February 1, 2011

DSM sees majority of its growth from emerging economies

DSM expects 75% of its growth to come from emerging markets over the next five years, said Chief Executive Feike Sijbesma.

Already before the crisis the growth was coming from the emerging economies, but now it's even stronger, said Sijbesma.

Feike Sijbesma also mentioned that he was looking at further acquisitions and reiterated the company could spend more than EUR2 billion (US$2.7 billion). DSM hit the acquisition trail last month by agreeing to buy US baby food ingredients maker Martek Biosciences for US$1.1 billion.

"We have almost no net debt, so we still believe that this is a good moment for M&A deals," Sijbesma said.